Abstract:We report a case of Epstein-Barr virus (EBV) primo infection with the development of successive infectious mononucleosis, hemophagocytic lymphohistiocytosis, and B-cell lymphoproliferative disorder in a patient treated with azathioprine for Crohn's disease. This case report suggests that specific EBV-related clinical and virological management should be considered when treating a patient with inflammatory bowel disease with azathioprine.
“…3,8,9,12,13 Rituximab is a humanized anti-CD20 monoclonal antibody which targets and depletes mature B cells within 48 h of therapy. In relation to HLH, the inclusion of rituximab may rapidly reduce the numbers of B cells containing EBV; it is these cells that are thought to drive the dysregulation of the inflammatory response.…”
Section: How Would You Treat/manage This Patient?mentioning
confidence: 99%
“…Recently patients treated with azathioprine for Crohn's disease have also been found to be at risk. [3][4][5][6][7] In addition to HLH, the differential should also include various malignancies, including leukaemia, infections and rheumatoid disorders.…”